Gavin Koh
Chief Medical Officer
Gavin has over 10 years of experience in drug development in the pharmaceutical industry. At AstraZeneca, he was product lead for Evusheld, an antibody combination for the prevention of COVID-19. During the pandemic, he took the product from phase 1 to authorisation in just over a year.
At GSK, he led the tafenoquine (Krintafel) phase 3 programme, the first new drug against vivax malaria in over 60 years. He led multiple early-stage programmes from discovery into the clinic at GSK and in the biotech arena.
Gavin qualified in Medicine at Cambridge University and completed his specialist training in Infectious Diseases in Birmingham, England. He obtained his PhD at Cambridge and Oxford in Infectious Diseases and Immunology. He joined RQ Biotechnology in July 2025.